Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01989221 · ClinicalTrials.gov registry record · Phase 3
Sancuso® for Gastroparesis: An Open Label Study.
A Phase 3 study of Gastroparesis, sponsored by Temple University.
- Completed
- Registry status
- Phase 3
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT01989221: Completed Phase 3 study of Gastroparesis, sponsored by Temple University.
NCT01989221 is a Phase 3 study of Gastroparesis that has completed, run by Temple University. The registered enrollment target is 14 participants, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01989221, a Phase 3 study of Gastroparesis, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to determine the efficacy of Sancuso® (granisetron transdermal system) 3.1 mg/24 hours in improving symptoms of nausea and vomiting in patients with gastroparesis. This will be a prospective open-label study using Sancuso® to treat symptoms of nausea and/or vomiting in patients diagnosed with gastroparesis. Symptomatic patients with diabetic or idiopathic gastroparesis with nausea and/or vomiting will be enrolled. The Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD) will be used to capture the severity of symptoms, including nausea and vomiting, at baseline for one week. Patients will then be treated with Sancuso®. Patients will continue to fill out the GCSI-DD on a daily basis while undergoing treatment with Sancuso® for two weeks. To determine if Sancuso® treatment helps improve symptoms of nausea and vomiting, the symptoms at baseline will be compared to symptoms after the first week and the second week of treatment. Thirty patients diagnosed with gastroparesis (approximately 15 with diabetic and 15 with idiopathic gastroparesis) will be treated on an open label basis with Sancuso®. The goal of this study is to demonstrate the efficacy of Sancuso® in treating nausea and/or vomiting in gastroparesis patients. Safety information will also be collected regarding any adverse effects. If the results are encouraging, as we expect them to be based on personal experience, a larger double blind study would be appropriate.
Primary Outcome
The Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD) was used to capture the severity of symptoms during one week at baseline and two weeks of treatment with GTS. The GCSI-DD includes questions about severity of nausea, early satiety, postprandial fullness, upper abdominal pain, and overall symptoms. Patients rated their symptom severity on a scale of 0 (no symptom), 1 (mild), 2 (moderate), 3 (severe), and 4 (very severe) and recorded the number of vomiting episodes per day. A daily co
Conditions Studied
Interventions
- DRUG Sancuso®
Study Locations (1)
Pennsylvania
- Temple University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-11 |
| Est. Completion | 2018-12 |
| Phase | Phase 3 |
What the finished NCT01989221 record still lists
NCT01989221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Gastroparesis appearing as the primary indexed condition, and to 1 intervention - of which Sancuso® is the first listed.
NCT01989221 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01989221 about?
NCT01989221 is a clinical study titled "Sancuso® for Gastroparesis: An Open Label Study.". The aim of this study is to determine the efficacy of Sancuso® (granisetron transdermal system) 3.1 mg/24 hours in improving symptoms of nausea and vomiting in patients with gastroparesis. This will be a prospective open-label study using Sancuso® to treat symptoms of nausea and/or vomiting in patie...
What is the current status of trial NCT01989221?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 14 participants. The study started on 2012-11. Estimated completion is 2018-12.
What conditions does trial NCT01989221 study?
This clinical trial studies the following conditions: Gastroparesis.
What interventions are being tested in trial NCT01989221?
The interventions under investigation include: Sancuso® (DRUG).
Who is sponsoring clinical trial NCT01989221?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01989221 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroparesis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01989221's enrollment target sits among peer trials
14 39th of 44 higher than 5 of 44 other Gastroparesis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroparesis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
-
Gastroparesis Registry 4
RECRUITING
-
The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM
RECRUITING · NA
-
Study of Gastric Motility in Eosinophilic Gastritis
RECRUITING
-
Indiana University Gastrointestinal Motility Diagnosis Registry
RECRUITING
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia